Yonsei Medical Journal最新文献

{"title":"A Novel Sarcopenia Screening Approach Using an Osteoporosis-Inspired T-Score Method.","authors":"Hyun Sik Kim, Choon Hee Chung, Jung Woo Lee","doi":"10.3349/ymj.2024.0537","DOIUrl":"10.3349/ymj.2024.0537","url":null,"abstract":"<p><strong>Purpose: </strong>Sarcopenia is characterized by reduced muscle mass, strength, and impaired physical function, and it requires effective indicators for early detection. This study introduces a novel screening method using the expected muscle functionality (eMF) indicator and an osteoporosis-inspired T-score.</p><p><strong>Materials and methods: </strong>The model was developed using 4052 individuals from the Korea National Health and Nutrition Examination Survey (KNHANES) and validated with 888 individuals from the Korean Genome and Epidemiology Study (KoGES). eMF was calculated using logistic regression based on grip strength, body mass index (BMI), waist circumference, and age. The T-score was derived by standardizing eMF against the mean and standard deviation of young adults (aged 20-29 years). The T-score cut-off values were determined at the intersection of kernel density estimation plots, set at -1.1 for men and -1.8 for women. Sarcopenia was diagnosed in individuals below these cutoffs.</p><p><strong>Results: </strong>Performance metrics were calculated based on sarcopenia defined using cutoff values of grip strength and muscle mass. The model demonstrated reliable performance, with sensitivity, specificity, accuracy, and area under the receiver operating characteristic curve of 0.900, 0.889, 0.890, and 0.932, respectively. False negatives exhibited clinical characteristics similar to sarcopenic obesity, while false positives resembled possible sarcopenia.</p><p><strong>Conclusion: </strong>The eMF-based indicator offers a significant improvement in sarcopenia screening, enabling more accurate identification and supporting early detection and management of the condition, ultimately enhancing patient outcomes and healthcare delivery.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"647-656"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foveal Serous Retinal Detachment with Inferior Staphyloma: Long-Term Treatment Response to Anti-VEGF and Photodynamic Therapy.","authors":"Jae Won Jun, Soyoung Jeon, Goeun Park, Hyun Goo Kang, Christopher Seungkyu Lee, Min Kim, Sung Soo Kim, Suk Ho Byeon, Junwon Lee","doi":"10.3349/ymj.2024.0220","DOIUrl":"10.3349/ymj.2024.0220","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the treatment response and long-term prognosis of foveal serous retinal detachment (SRD) associated with inferior staphyloma to anti-vascular endothelial growth factor (anti-VEGF) treatment and photodynamic therapy (PDT).</p><p><strong>Materials and methods: </strong>Treatment-naïve patients who underwent >24 months of follow-up were included. We analyzed inter-visit changes in the foveal subretinal fluid (SRF) height after anti-VEGF treatment or PDT compared to no treatment and long-term prognosis of best-corrected visual acuity in choroidal neovascularization (CNV)-free patients.</p><p><strong>Results: </strong>Nineteen patients were enrolled, and the mean follow-up duration was 4.81 years. In 14 CNV-free patients, 11 received anti-VEGF injections, three patients underwent PDT, and two patients had both treatments. During the follow-up period, there were a total of 243 inter-visit events (88 injections and 155 observations without treatment). At the last visit of patients who received the treatment, complete resolution was more significantly achieved in the CNV group than in the CNV-free group (<i>p</i>=0.028). In CNV-free patients, visual acuity improved when complete resolution was achieved; otherwise, it generally decreased. After adjusting for confounding factors, analyses showed no statistically significant differences in inter-visit changes of foveal SRF height between the anti-VEGF treatment and no treatment cases (absolute value, rate, subgroup categorized as ±20% of change; <i>p</i>=0.733, <i>p</i>=0.916, <i>p</i>=0.277; respectively). All patients who underwent PDT did not show complete resolution or maintained improvement of SRF.</p><p><strong>Conclusion: </strong>Treatment with anti-VEGF and PDT do not seem to be effective for foveal SRD of CNV-free inferior staphyloma.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"666-674"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Usefulness of a Multigene Testing in Patients with Special Histologic Type Breast Cancer.","authors":"Suk Jun Lee, Jung Min Park, Jee Hyun Ahn, Chan Seok Yoon, Seho Park","doi":"10.3349/ymj.2024.0408","DOIUrl":"10.3349/ymj.2024.0408","url":null,"abstract":"<p><strong>Purpose: </strong>Rare special histologic types of breast cancer usually show a favorable prognosis but often has atypical features. Multigene tests (MGTs) in patients with special types of breast cancer have not been well studied. Therefore, we aimed to examine the association between MGTs and histopathology and to evaluate the prognosis of MGTs in patients with special types of breast cancer.</p><p><strong>Materials and methods: </strong>A total of 133 patients with special histologic types of breast cancer who underwent MGTs were selected from two institutions from 2013 to 2022. Special types were divided into favorable and unfavorable groups. The patients' clinicopathological characteristics and MGT results were compared, and disease-free survival (DFS) was analyzed.</p><p><strong>Results: </strong>The unfavorable group consisted of 76 (57.1%) patients and included more older patients, multiple tumors, grade II/III tumors, high-risk MGT results, and chemotherapy administration. High-risk MGTs were found in 16.5% of the total cohort. The unfavorable type tended to have high-risk MGTs, but multivariate analysis demonstrated that grade II/III tumors, low progesterone receptor expression, and high Ki-67 levels were associated with high-risk MGTs in special type breast carcinomas. MGTs were significantly associated with DFS, particularly in the unfavorable subgroup, in which no recurrence occurred among patients with low-risk MGTs.</p><p><strong>Conclusion: </strong>Unfavorable special types of breast cancer were more likely to have high-risk MGTs. The MGT result was a significant prognostic factor and could support decision-making for adjuvant therapies in patients with special histologic types of breast cancer.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"630-636"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hearing Rehabilitation with Osia^®2 in Patients with Bonebridge^® Failure.","authors":"Ji Min Yun, Yunbin Nam, Gerard Lapina, In Seok Moon","doi":"10.3349/ymj.2024.0437","DOIUrl":"10.3349/ymj.2024.0437","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to compare the clinical performance and patient satisfaction of the Osia^®2 system with the Bonebridge^® system in patients requiring reimplantation owing to Bonebridge^® device malfunction.</p><p><strong>Materials and methods: </strong>A retrospective chart review was conducted on seven patients who initially received Bonebridge^® and subsequently underwent reimplantation with Osia^®2 following device failure. Audiological outcomes were evaluated using pure tone audiometry and the Korean Hearing in Noise Test. Subjective outcomes were assessed with the Abbreviated Profile of Hearing Aid Benefit (APHAB) and Speech, Spatial and Qualities of Hearing Scale (SSQ).</p><p><strong>Results: </strong>Osia^®2 provided greater low-frequency gain and comparable high-frequency gain compared to Bonebridge^®. The median hearing gain with Osia^®2 was 60.0 dB (interquartile range, 48.75-83.0), consistent with previous findings for this model and higher than those reported for the earlier Osia^® model. Patient questionnaires indicated significant improvements in APHAB and SSQ scores with Osia^®2 compared to both unaided and Bonebridge^®-aided conditions.</p><p><strong>Conclusion: </strong>The Osia^®2 system demonstrated audiological outcomes and patient satisfaction comparable to the Bonebridge^® system in this reimplantation cohort. Osia^®2 may be a favorable option for patients with conductive or mixed hearing loss or single-sided deafness, pending further studies on long-term device reliability.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"695-702"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positive Relationships between Intraocular Pressure and Thyroid Function in Graves' Ophthalmopathy: A Three-Aspect Evidence Analysis.","authors":"Wenhua Zhang, Feng Zhang, Ziyi Zhu, Jiamin Cao, Wei Xiong","doi":"10.3349/ymj.2024.0468","DOIUrl":"10.3349/ymj.2024.0468","url":null,"abstract":"<p><strong>Purpose: </strong>High intraocular pressure (IOP) is a frequent clinical manifestation of Graves' ophthalmopathy (GO), but little is known about the mechanism by which thyroid function alters IOP in GO.</p><p><strong>Materials and methods: </strong>The relationships between IOP and clinical manifestations of GO were determined by simple linear correlation analysis and the Kruskal-Wallis test. Factors significantly associated with changes in IOP were evaluated by multiple linear regression analysis. The relationships between IOP and thyroid function were verified using data from the National Health and Nutrition Examination Survey, and causative relationships between thyroid function and IOP were assessed using summary-data-based Mendelian randomization analysis. Gene expression was compared in patients with and without GO using analysis of a Gene Expression Omnibus dataset, and associated GO pathways were identified.</p><p><strong>Results: </strong>Clinical data were obtained from 392 hospitalizations of 270 patients, including 142 hospitalizations with increased IOP and 250 with normal IOP. IOP was linearly associated with GO duration, clinical activity score (CAS), and concentrations of free triiodothyronine (FT3), free thyroxine (FT4), and thyrotropin receptor antibodies. Multiple linear regression analysis yielded a model including CAS, FT3 concentration, and sex (r=0.46). Analysis of 3848 samples from the dataset showed that FT3 and FT4 levels differed between the increased and normal IOP groups. Increased expression of the <i>LOXL-AS1</i> gene was identified as a contributor to increased IOP, with <i>LOXL-AS1</i> expression increased in GO.</p><p><strong>Conclusion: </strong>Increased thyroid function is a risk factor for elevated IOP in patients with GO, with higher expression of <i>LOXL-AS1</i> in GO contributing to this effect.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"675-684"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Significant Improvement in Long-Term Survival after Liver Resection for Hepatocellular Carcinoma: Evolving Outcomes over 20 Years.","authors":"Na Reum Kim, Gi Hong Choi, Dai Hoon Han, Kyung Sik Kim, Jin Sub Choi","doi":"10.3349/ymj.2024.0087","DOIUrl":"10.3349/ymj.2024.0087","url":null,"abstract":"<p><strong>Purpose: </strong>Advanced techniques and multidisciplinary approaches have improved hepatocellular carcinoma (HCC) surgical outcomes. This study updates the long-term survival after liver resection (LR) for HCC based on over 20 years of experience.</p><p><strong>Materials and methods: </strong>Between 1996 and 2017, 1963 patients with HCC underwent LR. After excluding 185 patients who received preoperative therapy, 1778 treatment-naïve HCC patients were included. Clinicopathological characteristics and surgical outcomes were compared across three periods: 1 (1996-2007), 2 (2008-2012), and 3 (2013-2017). Prognostic factors for overall survival (OS) and disease-free survival (DFS) were analyzed using Cox regression analysis.</p><p><strong>Results: </strong>Recent trends indicate increased diagnoses at older ages, number of non-B and non-C HCC cases and decreased incidence of cirrhosis. Minor, non-anatomical, and minimally invasive LR have become more prevalent. In period 3, short-term outcomes improved, as 90-day mortality decreased to 0.3% and major complications to 5.0%. Long-term outcomes improved (5-year OS: 68.1% vs. 80.7% vs. 90.5%, <i>p</i><0.001; 5-year DFS: 41.4% vs. 50.7% vs. 61.1%, <i>p</i><0.001), and early recurrence rates decreased in period 3 (34.0% vs. 34.0% vs. 25.8%, <i>p</i><0.001). Factors such as smaller tumor size, decreased incidence of cirrhosis, fewer intraoperative transfusions, and fewer major complications have contributed to improved OS and DFS.</p><p><strong>Conclusion: </strong>Remarkable improvements in 5-year OS and DFS were observed after curative LR for HCC, particularly in period 3. Advancements in surgical outcomes, including very low short-term mortality, along with improved surgical techniques, early detection, and refined patient selection, are likely key factors in this progress.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"637-646"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Adherence to Digital Cognitive Behavioral Therapy for Insomnia Effectiveness.","authors":"Suonaa Lee, Kyung Mee Park, Do Hyun Lee, Eun Chae Choi, Yujin Lee, Eun Lee","doi":"10.3349/ymj.2024.0398","DOIUrl":"10.3349/ymj.2024.0398","url":null,"abstract":"<p><strong>Purpose: </strong>Although digital cognitive behavioral therapy for insomnia (dCBT-I) offers a promising solution to the accessibility limitations of traditional face-to-face CBT-I, few studies have examined dCBT-I against a sham app and adherence issues remain. This study assessed the efficacy of dCBT-I compared with a sham app and investigated whether adherence predicts sleep outcomes.</p><p><strong>Materials and methods: </strong>In this combined analysis of two multicenter, double-blind, sham-controlled randomized controlled trials, 120 patients with insomnia were randomized to use the dCBT-I app (n=60) or a sham app (n=60). The primary outcome was the change in sleep efficiency (SE) from baseline after the 6-week intervention. The relationship between adherence to sleep restriction therapy (SRT) and sleep outcomes post-intervention was assessed.</p><p><strong>Results: </strong>After adjusting for age, sex, sleep medication use, and baseline levels of each outcome variable, the dCBT-I group demonstrated better treatment outcomes than the sham app group, with significant improvements of 7.69% in SE [95% confidence interval (CI), 3.09% to 12.30%; <i>p</i>=0.001], -16.77 minutes in sleep onset latency (95% CI, -31.48 to -2.06 minutes; <i>p</i>=0.026), and -0.97 in dysfunctional beliefs about sleep (95% CI, -1.46 to -0.48; <i>p</i><0.001) from baseline. Poorer adherence to SRT was associated with reduced SE (<i>p</i>=0.006) and increased nighttime wakefulness (<i>p</i>=0.002) after controlling for age, sex, years of education, and the baseline value of each outcome variable.</p><p><strong>Conclusion: </strong>This combined analysis demonstrates the efficacy of dCBT-I in improving sleep outcomes compared with a sham app and highlights the role of adherence to SRT in enhancing treatment efficacy. The two studies were registered with ClinicalTrials.gov (NCT05822999, NCT05809544).</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"657-665"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acidic Tumor Microenvironments and Emerging Therapeutic Strategies for Cancer Therapy.","authors":"Yongzhi Zhuang, Liquan Tong, Xueying Sun","doi":"10.3349/ymj.2024.0210","DOIUrl":"10.3349/ymj.2024.0210","url":null,"abstract":"<p><p>Hypoxia and acidity represent two distinct properties of tumor microenvironments (TMEs). Tumor acidity was initially proposed to be a \"by-product\" of hypoxia, which results from abnormal vasculature and excessive oxygen demands. It is now recognized that acidity has its unique function in TMEs, as it can exacerbate abnormal cellular energy metabolism, inhibit cellular carcinogen metabolism, impede DNA damage repair mechanisms, and suppress immune cell activation, all of which play crucial roles during carcinogenesis. Acidic TMEs are also major contributors to the invasion and metastasis of tumor cells, and participate in the mechanisms underlying resistance to cancer treatments including immunotherapy. Therefore, the development of novel anti-cancer agents that target acidic TMEs may have considerable clinical benefits. This article reviews the updated information in this rapidly growing field, including the influence of acidic TMEs on cancer progression, resistance to current treatments and anti-cancer immunity, and their association with hypoxia and aerobic glycolysis. It also summarizes the key molecules that contribute to acidic TMEs and highlights the development of anti-cancer agents targeting tumor acidity, primarily inhibitors of carbonic anhydrases, monocarboxylic acid transporters, vacuolar-type adenosine triphosphatase (V-ATPase), and Na⁺/H⁺ exchangers. At present, none of the inhibitors targeting acidic TMEs have been approved for clinical use in cancer treatment, except for proton pump inhibitors that target V-ATPase. Development of highly specific agents and the discovery of more sensitive and precise biomarkers may help improve the effectiveness of these inhibitors for cancer therapy.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 10","pages":"619-629"},"PeriodicalIF":2.8,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12479195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145138995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients.","authors":"Jae-Hyuk Jang, ChulHyoung Park, Chungsoo Kim, Youngsoo Lee, Eunyoung Lee, Rae Woong Park, Hae-Sim Park","doi":"10.3349/ymj.2024.0320","DOIUrl":"https://doi.org/10.3349/ymj.2024.0320","url":null,"abstract":"<p><strong>Purpose: </strong>Omalizumab improves clinical outcomes for patients with severe asthma (SA), but its long-term effectiveness and potential biomarkers for predicting patient response require further investigation. This study aimed to evaluate the real-world effectiveness of omalizumab in treating SA and to identify potential biomarkers for predicting a favorable treatment response.</p><p><strong>Materials and methods: </strong>Clinical outcomes were compared between asthma patients receiving omalizumab (omalizumab group) and those on inhaled corticosteroid with long-acting beta-agonist (ICS-LABA) alone (ICS-LABA group). Propensity score matching and Cox proportional hazards model were used to calculate hazard ratios (HRs). Study outcomes included severe asthma exacerbation (SAE), incompletely controlled asthma, intravenous (IV) corticosteroid use, and asthma-related hospitalization. Incompletely controlled asthma was defined by blood eosinophil counts ≥150 cells/µL, fractional exhaled nitric oxide (FeNO) ≥25 ppb, forced expiratory volume in one second (FEV1%) <80%, or SAE occurrence.</p><p><strong>Results: </strong>The omalizumab group had significantly lower risks of SAE (HR 0.17, <i>p</i>=0.03), incompletely controlled asthma (HR 0.56, <i>p</i>=0.04), IV corticosteroid treatment (HR 0.38, <i>p</i>=0.02), and asthma-related hospitalization (HR 0.27, <i>p</i>=0.05). Blood eosinophil count stayed lower in the omalizumab group. FEV1% was higher with the omalizumab group, while blood neutrophil count, FeNO, and serum total IgE showed no differences. Furthermore, subgroup analysis showed patients with treatment-favorable response (>50% reduction in systemic corticosteroid dose) exhibited decreased blood neutrophil counts but increased FEV1% and serum total IgE levels compared with the treatment-unfavorable group.</p><p><strong>Conclusion: </strong>Omalizumab treatment effectively reduces SAE and improves lung function and asthma control. Blood neutrophil counts and serum total IgE may be potential biomarkers for predicting favorable responses to omalizumab treatment.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 9","pages":"545-555"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144971419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectories of Alzheimer's Disease Prevalence among National Health Insurance and Medical Aid Beneficiaries from 2010 to 2019.","authors":"Sanghyun Kim, Changsoo Kim, Yoon Jung Choi","doi":"10.3349/ymj.2024.0303","DOIUrl":"https://doi.org/10.3349/ymj.2024.0303","url":null,"abstract":"<p><strong>Purpose: </strong>Alzheimer's disease (AD) is the leading cause of dementia and is associated with various socioeconomic factors. This study aimed to ascertain the differences in AD prevalence based on healthcare coverage type as a proxy of socioeconomic status in South Korea.</p><p><strong>Materials and methods: </strong>We examined Health Insurance Review and Assessment Service claims from 2010-2019, identifying AD as the main disease. Crude prevalence rate and age- and sex-standardized prevalence were estimated from healthcare utilization data. Subgroup analysis by age, sex, comorbidities (hypertension, diabetes, and cardiovascular disease), and type of healthcare coverage [Medical Aid (MA) vs. National Health Insurance (NHI)] was performed to estimate the standardized prevalence rate ratio (PRR).</p><p><strong>Results: </strong>AD prevalence increased 3.9 times from 2010 (175688 cases) to 2019 (680800 cases). In the NHI group, the standardized prevalence increased 2.3-fold (624.4 in 2010 and 1433.2 in 2019), whereas the MA group saw a 2.7-fold increase (1251.0 in 2010 and 3391.9 in 2019). AD was significantly higher in the MA group from 2010 [PRR=2.00, 95% confidence interval (CI) 1.98-2.03] to 2019 (PRR=2.37, 95% CI 2.35-2.38) compared to the NHI group. From 2010 to 2019, a proportion of comorbidities increased in MA and NHI groups. Compared to the NHI group, the MA group showed significantly higher proportion of comorbidities.</p><p><strong>Conclusion: </strong>In this study, we identified significant differences in AD prevalence between NHI and MA recipients, with a notable increase in the MA group, especially among those under 60 years of age.</p>","PeriodicalId":23765,"journal":{"name":"Yonsei Medical Journal","volume":"66 9","pages":"590-598"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12394758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144971439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}